朱咪咪;孔梦影;郭燕;于兵;别福鑫;张丽;

• 1:牡丹江医学院
• 2:牡丹江医学院附属红旗医院呼吸内科

摘要(Abstract)：

慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种常见的以持续性呼吸道症状和气流受限为特征的可以预防和治疗的疾病,随着疾病的进展,肺功能逐渐减退,引起一系列并发症及多器官受累。目前,COPD的发病机制仍无定论,氧化性应激、蛋白酶/抗蛋白酶失衡、炎性细胞及炎性介质、细支气管周和肺间质纤维化是COPD发病机制的关键环节。本文结合相关文献,对COPD发病机制、危险因素、诊断治疗的研究进展作一综述。

关键词(KeyWords)： 慢性阻塞性肺疾病;;发病机制;;危险因素;;诊断;;治疗

Abstract:

Keywords:

基金项目(Foundation): 黑龙江省卫生计生委科研课题(2016-389)

作者(Author): 朱咪咪;孔梦影;郭燕;于兵;别福鑫;张丽;

Email:

参考文献(References)：

• [1]王蕾,杨汀,王辰,等.2017年版慢性阻塞性肺疾病诊断、处理和预防全球策略解读[J].中国临床医生杂志2017,45(1):104-108.
• [2]房建珍,毕丽岩.慢性阻塞性肺疾病急性加重期诊治新进展[J].医学与哲学,2013,483(34):57-60.
• [3]JOHNSON S R.Untangling the protease web in COPD:metalloproteinases in the silent zone[J].Thorax,2016,71(2):105-106.
• [4]YOSHIDA,TOSHINORI,TUDER,et al.Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease[J].Physiological Reviews,2007,87(3):1047-1082.
• [5]KOPF M,SCHNEIDER C,NOBS S P.The development and function of lung-resident macrophages and dendritic cells[J].Nat Immunol,2015,16(1):36-44.
• [6]刘雪青,姜鲁宁,宋敏.树突状细胞对慢性阻塞性肺疾病的诊断意义[J].中国免疫学杂志,2015,31(5):678-682.
• [7]EISNER M D,ANTHONISEN N,COUNLTAS D,et al.An Official American Thoracic Society Public Policy Statement:Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease[J].Am J Resoir Crit Care Med,2010,182(5):693-718.
• [8]兰丰铃,王胜锋,曹卫华,等.慢性阻塞性肺疾病危险因素流行病学研究新进展[J].中华疾病控制杂志,2014,18(10):998-1002.
• [9]FORER B A,THORNTON A J,LEE P N.Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD,chronic bronchitis and emphysema[J].BMC Pulm Med,2011,11:36.
• [10]WANG B Y,XIAO D,WANG C.Smoking and chronic obstructive pulmonary disease in Chinese population:a meta-analysis[J].Clinical Respiratory Journal,2015,9(2):165-175.
• [11]张洁如,朱慕云.慢性阻塞性肺疾病相关基因位点及后天获得性基因改变[J].中华肺部疾病杂志,2015,8(4):495-497.
• [12]HERSH C P,HOKANSON J E,LYNCH D A,et al.Family history is a risk factor for COPD[J].Chest,2011,140(2):343-350.
• [13]ASSAD N A,KAPOOR V,SOOD A.Biomass smoke exposure and chronic lung disease[J].Curr Opin Pulm Med,2016,22(2):150-157.
• [14]VOGELMEIER C F,CRINER G J,MARTINEZ F J,et al.Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Lung Disease 2017 Report[J].Respirology,2017,22(3):575-601.
• [15]ALBERT P,AGUSTI A,EDWARDS L,et al.Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease[J].Thorax,2012,67(8):701-708.
• [16]沈国森,徐致远.血清降钙素、C反应蛋白、白细胞计数对细菌性感染的诊断价值研究[J].中国现代医生,2013,6(8):67-69.
• [17]梅春霞,刘娟,徐智,等.APACHEⅡ评分和降钙素原对肺部感染预后的预测作用[J].第三军医大学学报,2014,8(8):802-805.
• [18]樊海燕.降钙素原在感染性疾病中的应用价值[J].现代中西医结合杂志,2015,6(1):89-91.
• [19]卢仁辉,陈婉婷,孙晓丽,等.肺部感染急性加重期慢性阻塞性肺疾病患者血清C反应蛋白和降钙素原及CD64感染化研指数变究[J].中华医院感染学杂志,2017,27(7):1514-1517.
• [20]SIDDIQUI S H,GUASCONI A,VESTBO J,et al.Blood Eosinophils:A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease[J].Am J Respir Crit Care Med,2015,192(4):523-525.
• [21]田苗,解学星,马璐,等.新一代吸入型长效β2受体激动剂奥达特罗[J].现代药物与临床,2013,28(2):227-231.
• [22]李海玲,李凡.GOLD2017更新要点解读及其对中国慢性阻塞性肺疾病分级诊疗的启示[J].中国全科医学,2017,18(20):2171-2175.
• [23]VOGELMEIER C,HEDERER B,GLAAB T,et al.Tiotropium versus salmeterol for the prevention of exacerbations of COPD[J].N Engl J Med,2011,364(12):1093-1103.
• [24]DECRAMER M L,CHAPMAN K R,DAHL R,et al.Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease(INVIGORATE):a randomised,blinded,parallel-group study[J].Lancet Respir Med,2013,1(7):524-533.
• [25]张国富.糖皮质激素在COPD治疗中的应用[J].中国社区医师,2015,31(16):10-11.
• [26]IMRAN S,BEEDA C,GARRETT G,et al.Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease[J/OL].Am J Respir Crit Care Med,2016,195(10):1333-1343.
• [27]杨帆,霍建民.慢性阻塞性肺疾病急性加重期的抗生素应用进展[J].中化临床医生杂志(电子版),2013,7(15):7145-7148.
• [28]张弘,蔡柏蔷.慢性阻塞性肺疾病急性加重临床研究进展[J].中国呼吸与危重监护杂志,2016,5(2):198-222.